Drug intelligence / Profile preview

doxazosin + valsartan

Development stage
Preclinical
Lead developer
Pfizer
Modality
Small Molecules
Administration
Oral
01

Overview

**Doxazosin + valsartan** is a combination of two antihypertensive agents: doxazosin, an alpha-1 adrenergic receptor antagonist, and valsartan, an angiotensin II receptor blocker (ARB). Doxazosin works by blocking alpha-1 adrenergic receptors, resulting in vasodilation of veins and arteries, thereby lowering blood pressure and relaxing smooth muscles in the bladder neck and prostate[5][7]. Valsartan blocks the angiotensin II type 1 receptor, inhibiting the effects of angiotensin II, which normally causes vasoconstriction and increased aldosterone secretion[1]. This combination can be used as add-on therapy for patients whose hypertension is inadequately controlled by valsartan alone, resulting in further reduction of blood pressure[4]. No unique brand name formulation with this exact combination appears to be marketed, but clinical studies have evaluated its use in combination therapy.

Other names
doxazosin + valsartan
02

Targets

AGTR1 (Angiotensin II Type-1 receptor)ADRA1A (α1A)

Beyond the preview

Go deeper on doxazosin + valsartan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on doxazosin + valsartan.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call